Relatedly, growth of renal cell carcinoma is claimed to depend on dysregulation of the FGF/FGF-receptor 1 (FGFR1) cell signaling pathway, yet pharmaceutical inhibition of this pathway blocks circulating levels of FGF23 and causes hyperphosphatemia [90]. This evidence concerns the gene FGFR1 and hyperphosphatemia.